Huayi Technology's Recap of the 63rd JSNM Annual Meeting and 43rd JSNMT Annual Meeting in 2023

The 63rd Annual Meeting of the Japanese Society of Nuclear Medicine (JSNM) and the 43rd Annual Meeting of the Japanese Society of Nuclear Medicine Technology (JSNMT) took place in Osaka from November 16th to 18th, attracting experts from around the world. The theme of this conference was "Learn and Create Nuclear Medicine - Everyone is the Heroine/Hero!" with the aim of encouraging everyone to play a leading role in the practice and innovation of nuclear medicine.

Huayi Technology was honored to participate in this grand event, welcoming esteemed experts such as Professor Huo Li, Director of the Nuclear Medicine Department at Peking Union Medical College Hospital, Professor Zhang Hong, Dean of the School of Biomedical Engineering and Instrument Science at Zhejiang University, and their respective teams, as well as Professor Wu Jin, Visiting Professor at Peking University First Hospital, who pursued further studies at the University of Tsukuba in Japan and obtained a doctoral degree. Professor Wu has been actively engaged in basic and clinical research in the field of nuclear medicine and molecular imaging, contributing significantly to the development of nuclear medicine in both China and Japan. The opportunity to meet her at the exhibition was indeed rare.At the booth, experts highly praised Huayi Technology's technical strength and product innovation. They emphasized the critical importance of technological advancement and the development of novel radiopharmaceuticals in the field of nuclear medicine for enhancing clinical diagnosis and treatment, as well as providing more precise therapeutic solutions.

This conference marked a crucial step for us in deepening international cooperation and learning from advanced international experiences. As Professor Makoto Hosono, the Chairman of the conference, mentioned, nuclear medicine has rapidly advanced in recent years. In the field of oncologic nuclear medicine, lutetium-177 DOTATATE for treating neuroendocrine tumors and iodine-131 MIBG for treating pheochromocytoma and paraganglioma were approved as radiotherapies in 2021. Radium-223 was approved in 2016 as an alpha therapy, and subsequently, extensive efforts have been made to develop emerging alpha therapies. Huayi is poised to seize the opportunities arising from these developments, recognizing the importance and challenges of this task. We will delve into understanding new technologies and methods, stay attuned to the latest developments in the field of nuclear medicine, and engage in exchanges and collaborations with peers to ensure a comprehensive understanding of the latest trends and technologies. Let us meet again at JSNM 2024 in Yokohama, Japan!